Fast Forward has a vision – a world free of multiple sclerosis – a vision you undoubtedly share.
More than 2.1 million people worldwide are affected by MS, a chronic and unpredictable disease. Millions of dollars are invested annually in critical research, and have led to the FDA-approved drugs in existence today. These drugs may slow the progression of the disease for some, but for others, these drugs do nothing at all. People with MS need more treatment options now.
Fast Forward acts as a catalyst, connecting people, ideas, and vital resources to accelerate the development of new treatments for people with MS. We bridge the gap between groundbreaking research knowledge, and the commercial resources necessary to move those discoveries into the drug development process. Bringing treatments to people with MS - Faster.
Fast Forward News:
- Fast Forward Partners With Accera, Inc., and the University of Miami's Miller School of Medicine in a Clinical Trial to Determine Potential Benefits of Axona® on Cognitive Impairment in People With MS
- Canbex Therapeutics Raises $ 3.2 million to Develop Treatment for Debilitating Muscle Spasms Associated with MS
- Fast Forward and EMD Serono Provide Funding of up to $1.4 million in 2012 to Accelerate Early-Stage Research in MS
- Fast Forward Partner Apitope International N.V. Reaches Key Milestone in Phase I Peptide Therapy Study
- Fast Forward Collaborations Aim to Speed MS Diagnosis and Monitoring
- Research Supported by Fast Forward May Hold Key to Repairing Myelin Lost to Multiple Sclerosis
- Fast Forward Funds Axxam SpA for the Development of Compounds to Help Prevent Disability in Multiple Sclerosis
- Xconomy.com highlights how Fast Forward is helping young biotech firms speed the development of potential new MS therapies
- Fast Forward and Concert Pharmaceuticals Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis
- Fast Forward and Lineagen to Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis
- Fast Forward and Athersys enter Collaboration to Support Development of MultiStem to Treat Multiple Sclerosis
- Three-Way Research Partnership Could Hold Benefits for Both Type 1 Diabetes and Multiple Sclerosis
- Fast Forward and EMD Serono Provide Funding of Over $1 million to Accelerate Early Stage Research in MS
- Canbex Therapeutics Receives £1.75 million (USD 2.8 million) from the Wellcome Trust for Translational Research to Develop Treatment for Debilitating Muscle Spasms Associated with MS
- Society Convenes Think Tank on Progressive MS
- Dr. Timothy Coetzee Named Chief Research Officer by the National Multiple Sclerosis Society
- Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provid's Unique MS Drug Candidate
- Innate Therapeutics Initiates Phase 2 Testing of MIS416 in Patients With Progressive Multiple Sclerosis
- Fast Forward Funds Development of New Symptom Treatment for Multiple Sclerosis
- Fast Forward, LLC and Five Prime Therapeutics, Inc. Collaborate on Development of Innovative Biological Molecule to Speed New Treatments to People with Multiple Sclerosis
- Cognosci Inc. of Research Triangle Park receives funding support through Fast Forward
- BioBusiness for the Week Ended January 22 - BioCentury Part II
- MS, Diabetes Groups Form Partnership With Italian Biotech In Drug-Discovery Effort
- Fast Forward in MS - Science — Business eXchange
- Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes
- Small Biotechs Increasingly Seek Funds From Nonprofit Groups
- MS Society Teams with Merck KGaA on $19M R&D Pact
- Merck Collaboration to Fast Forward MS Drug Development
